Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

Journal of Clinical Investigation

Volumn 102, Issue 9, 1998, Pages 1674-1681

  Patel, Vyomesh ^a   Senderowicz, Adrian M ^b   Pinto Jr , Decio ^a   Igishi, Tadashi ^a   Raffeld, Mark ^b   Quintanilla Martinez, Leticia ^b   Ensley, John F ^c   Sausville, Edward A ^b   Gutkind, J Silvio ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antineoplastic agents; Cell cycle; Cell death; Oral cancer; Oral xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; FLAVOPIRIDOL; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DNA CONTENT; FEMALE; GAMMA IRRADIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

EID: 0032212885     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI3661     Document Type: Article

References (40)

1. National Cancer Institute, Cancer Statistics Review: 1973-1988. 1991. NCI, Division of Cancer Prevention and Control, Surveillance Program. NIH publication 91-2789, Bethesda, MD.
2. Devesa, S.S., W.J. Blot, B.J. Stone, B.A. Miller, R.E. Tarone, and J.F. Fraumeni, Jr. 1995. Recent cancer trends in the United States. J. Natl. Cancer Inst. 3:175-182.
3. Rosenberg, D., and S. Cretin. 1989. Use of meta-analysis to evaluate tolonium chloride in oral cancer screening. Oral Surg. Oral Med. Oral Pathol. 67: 621-627.
4. Silverman, S. 1994. Oral cancer. Semin. Dermatol. 13:132-137.
5. Stell, P.M., and N.S. Rawson. 1990. Adjuvant chemotherapy in head and neck cancer. Br. J. Cancer. 61:779-787.
6. Siodlak, M.Z., P.M. Stell, J.A. Wilson, J.A. Green, R.S. Allison, D. Adler, and M. Squadrelli-Saraceno. 1990. Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck. J. Laryngol. Otol. 104:631-633.
7. Boyd, M.R. 1997. The NCI in vitro anticancer drug discovery screen. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. B. Teicher, editor. Humana Press, Inc., Totowa, NJ. 23-42.
8. Weinstein, J.N., T.G. Myers, P.M. O'Connor, S.H. Friend, A.J. Fornace, Jr., K.W. Kohn, T. Fojo, S.E. Bates, L.V. Rubinstein, N.L. Anderson, et al. 1997. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:343-349.
9. Bates, S.E., A.T. Fojo, J.N. Weinstein, T.G. Myers, M. Alvarez, K.D. Paull, and B.A. Chabner. 1995. Molecular targets in the National Cancer Institute drug screen. J. Cancer Res. Clin. Oncol. 121:495-500.
10. Kaur, G., M. Stetler-Stevenson, S. Sebers, P. Worland, H. Sedlacek, C. Myers, J. Czech, R. Naik, and E. Sausville. 1992. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. 84:1736-1740.
11. Arguello, F., M. Alexander, J.A. Sterry, G. Tudor, E.M. Smith, N.T. Kalavar, J.F. Greene, Jr., W. Koss, C.D. Morgan, S.F. Stinson, et al. 1998. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood. 91:2482-2490.
12. Dress, M., W.A. Dengler, T. Roth, H. Labonte, J. Mayo, L. Malspeis, M. Grever, E.A. Sausville, and H.H. Fiebig. 1997. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clinical Cancer Res. 3:273-279.
13. Sedlacek, H.H., J. Czech, R. Naik, G. Kaur, P. Worland, M. Losiewicz, B. Parker, B. Carlson, A. Smith, A. Senderowicz, and E. Sausville. 1996. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 9:1143-1168.
14. Worland, P.J., G. Kaur, M. Stetler-Stevenson, S. Sebers, O. Sartor, and E.A. Sausville. 1993. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cell. Correlation with decreased H1 kinase activity. Biochem. Pharmacol. 46:1831-1840.
15. Losiewicz, M.D., B.A. Carlson, G. Kaur, E.A. Sausville, and P.J. Worland. 1994. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:589-595.
16. Carlson, B.A., M.M. Dubay, E.A. Sausville, L. Brizuela, and P.J. Worland. 1996. Flavopiridol induces G, arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56: 2973-2978.
17. Meijer, L., and S.H. Kim. 1997. Chemical inhibitors of cyclin-dependent kinases. Methods. Enzymol. 283:113-128.
18. Senderowicz, A.M., D. Headlee, S.F. Stinson, R.M. Lush, N. Kalil, L. Villalba, K. Hill, S.M. Steinberg, W.D. Figg, A. Tompkins, et al. 1998. Phase I trial of continuous infusion flavopiridol. a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16:2986-2999.
19. Chen, J.C., C.F. Shuler, C.X. Zhang, D.E. Schuller, and G.E. Milo. 1991. Histopathologic comparison between human oral squamous cell carcinomas and their xenografts in nude mice. Oral Surg. Oral Med. Oral Pathol. 71:457-463.
20. Cardinali, M., H. Pietraszkiewicz, J.F. Ensley, and K.C. Robbins. 1995. Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int. J. Cancer. 61:98-103.
21. Yeudall, W.A., R.Y. Crawford, J.F. Ensley, and K.C. Robbins, 1994. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis. 15:2683-2686.
22. Yeudall, W.A., J. Jakus, J.F. Ensley, and K.C. Robbins. 1997. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol. Carcinog. 182:89-96.
23. 1/S cyclins and cyclin-dependent kinases characterize squamous cell carcinomas of head and neck. Int. J. Cancer. 73:551-555.
24. Sherwood, S.W., and R.T. Schimke. 1995. Cell cycle analysis of apoptosis using flow cytometry. Methods. Cell Biol. 46:77-97.
25. Jakus, J., and W.A. Yeudall. 1996. Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Oncogene. 12:2369-2376.
26. Sellins, K.S., and J.J. Cohen. 1987. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. Immunol. 139:3199-3206.
27. Plowman, J., D.J. Dykes, M. Hollingshead, L. Simpson-Herren, and M.C. Alley. 1997. Human tumor xenograft models in NCI drug development. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. B. Teicher, editor. Humana Press, Inc., Totowa, NJ. 101-130.
28. Brynes, R.K., A. McCourty, R. Tamayo, K. Jenkins, and H. Battifora. 1997. Demonstration of cyclin D1 (Bcl-1) in mantle cell lymphoma. Appl. Immunohistochem. 5:45-48.
29. Czech, J., D. Hoffmann, R. Naik, and H.H. Sedlacek. 1995. Antitumoral activity of flavone L86 8275. Int. J. Oncol. 6:31-36.
30. Elledge, S.J. 1996. Cell cycle checkpoints: preventing an identity crisis. Science. 274:1664-1672.
31. Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108.
32. De Azevedo, W.F., Jr., H.J. Mueller-Dieckmann, U. Schulze-Gahmen, P.J. Worland, E. Sausville, and S.H. Kim. 1996. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA. 93:2735-2740.
33. Bartkova, J., J. Lukas, H. Muller, M. Strauss, B. Gusterson, and J. Bartek. 1995. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 55:949-956.
34. Michalides, R., N. van Veelen, A. Hart, B. Loftus, E. Wientjens, and A. Balm. 1995. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 55:975-978.
35. Michalides, R.J., N.M. van Veelen, P.M. Kristel, A.A. Hart, B.M. Loftus, F.J. Hilgers, and A.J. Balm. 1997. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 123:497-502.
36. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Houseman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
37. Strasser, A., D.C. Huang, and D.L. Vaux. 1997. The role of the bcl-2/ ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim. Biophys. Acta. 1333:151-178.
38. Parker, B.W., G. Kaur, W. Nieves-Neira, M. Taimi, G. Kohlhagen, T. Shimizu, M.D. Losiewicz, Y. Pommier, E.A. Sausville, and A.M. Senderowicz. 1998. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 91:458-465.
39. Bible, K.C., and S.H. Kaufmann. 1996. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 56:4856-4861.
40. Gallo, O., I. Chiarelli, S. Bianchi, A. Calzolari, L. Simonetti, and B. Porfirio. 1996. Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer. Clin. Cancer Res. 2: 1577-1582.